Events

One Nucleus | Genesis 2020 w/ Alix Lacoste

Hope, Hype and Reality of AI in Drug Discovery

Join BenevolentAI’s VP Applied Sciences at One Nucleus Genesis where she will be speaking on 'Hope, Hype and Reality of AI in Drug Discovery’.

Format

10 Minute Presentation: Introduction to what Pharma needs from AI with Vishal Sahni

10 Minute Presentation: Approaching AI in Drug Discovery with Alix Lacoste

Close: Q&A discussion on the potential and challenges of applying AI in drug discovery with:
Vishal Sahni | Director Discovery Research, MSD
Alix Lacoste | VP Applied Sciences, BenevolentAI
Steve Crossan | VP AI and ML at GSK
Rabia Khan


Alix Lacoste

VP Data Science, New York Site Lead

Alix has significant experience using data science and machine learning to advance biomedical discoveries. She holds a PhD in Molecular and Cellular Biology from Harvard University. Previously at IBM Watson Health, Alix led computational research projects in target identification and drug repurposing, most notably for Parkinson’s disease and amyotrophic lateral sclerosis, in collaboration with academic and pharma partners. At BenevolentAI, Alix connects AI and Drug Discovery groups to continuously improve the hypothesis generation pipeline.

More Posts

You Might Also Like

News
ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients
Peer-reviewed data from the ACTT-2 further validate BenevolentAI’s hypothesis for baricitinib as a potential COVID-19 treatment.
Jan 15, 2021
Blog
Joanna Shields speaks at the Global Partnership on Artificial Intelligence
BenevolentAI CEO Joanna Shields opened the final plenary of the Global Partnership on Artificial Intelligence (GPAI) summit with a powerful message on the future of AI.
Dec 11, 2020
Blog
BenevolentAI wins Innovation Award at 2020 Scrip Awards
BenevolentAI wins the Innovation Award at the prestigious 2020 Scrip Awards for our work in artificial intelligence applied drug discovery.
Dec 11, 2020
Intern at BenevolentAI part II: what to expect from your internship
What makes the best tech internships? Learn about what our 2020 interns have been up to, and how interning at Benevolent helped their career development.
Dec 2, 2020
Blog
Intern at BenevolentAI part I: meet our 2020 intern cohort
What impactful work did our interns get up to across Engineering, Data Science, ML and business operations this summer? Get to know them and their work in our tech internships blog.
Nov 26, 2020
News
FDA grants Emergency Use Authorisation for baricitinib in hospitalised COVID-19 patients nine months after initial hypothesis was published by BenevolentAI
BenevolentAI scientists first identified baricitinib as a potential treatment for COVID-19 in early February 2020 using Benevolent's AI tools and biomedical knowledge graph.
Nov 20, 2020